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1. Introduction 
Almost 100 years ago, Steinert (1909), Batten and Gibb (1909), independently described 
Myotonic Dystrophy type 1 (DM1) that is now recognized as the most common form of 
muscular dystrophies in adults and the second most common type of muscular dystrophy 
after Duchenne Muscular Dystrophy, affecting 1 in 8000 individuals globally (Harper, 1989). 
DM1 is a genetic disorder, which is inherited in an autosomal dominant fashion (the 
mutation in one copy of the affected allele is enough to cause the disease). Although the 
disease affects mainly the skeletal muscle, it is considered a multi-systemic disorder with 
variable clinical symptoms affecting skeletal muscle, heart, and the central nervous system 
(CNS) (Larkin & Fardaei, 2001). Individual patients with DM1 are often identified as having 
congenital, juvenile or adult-onset disease based on the age of symptom onset. Congenital 
cases display the most severe phenotype and face a neonatal mortality rate of 25% (Harper, 
1989).  
The involvement of skeletal muscle in DM1 is highly characteristic and largely unwavering. 
Skeletal muscle in DM1 displays progressive weakness and wasting, myotonia and pain. 
Moreover, at the early stages of the disease, DM1 patients exhibit facial and neck flexion 
muscle weaknesses. Also, ptosis and weakness of eye and mouth closure are classical facial 
changes observed in DM1 patients. Weakness of neck flexion is an early sign, and patients 
may notice difficulty in lifting their heads from the pillow or experience tendency for the 
head to fall backwards during acceleration of the vehicle in which they are traveling 
(Machuca-Tzili et al., 2005). At a later stage in the course of the disease, distal weakness in 
the limbs, affecting particularly the finger flexors causes substantial disability. Less marked 
but often occurring, the weakness of ankle dorsiflexion causes foot drop. The combination of 
facial muscle weakness (with ptosis) and distal muscle weakness in DM1, even in the 
absence of myotonia, does not occur in any other disease (Ranum & Day, 2002). Respiratory 
failure due to the weakness of the respiratory muscles can also occur. This may be lethal in 
some cases, and is presented mainly in DM1 patients that experienced anesthesia or suffered 
from various chest infections (Machuca-Tzili et al., 2005). Myotonia is demonstrable in most 
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symptomatic adults, whatever their symptoms. The commonest symptom of myotonia is 
difficulty in relaxing the grip. Myotonia can also affect the facial muscles, tongue, and other 
bulbar muscles, causing problems when talking, chewing and swallowing. Muscle pain is 
clearly independent to myotonia and more common in the lower limbs, where myotonia is 
usually not observed (Machuca-Tzili et al., 2005; Ranum & Day, 2002). Biopsies of DM1 
muscle show a markedly increased variation in fibre diameter that ranges from 10m to 
greater than 100m. Severely atrophic fibres have pygnotic nuclei with minimal remaining 
contractile elements. DM1 muscle observations also showed ring fibre and central nuclear 
chains. Moreover, ATPase staining of the affected muscle sections showed atrophy of type 1 
fibres. Finally, basophilic regenerating fibres, splitting fibres, fibrosis and adipose deposition 
are common muscle abnormalities of DM1, always depending on the extent of muscle 
involvement (Vihola et al., 2003).  
Antrioventricular and intraventricular conduction abnormalities are very common in DM1 
and require regular monitoring. DM1 patients were shown to be more vulnerable to cardiac 
conduction abnormalities than impaired myocardial function. Atrial fibrillation, ventricular 
arrhythmias and cardiomyopathy are also very common abnormalities in DM1 affected 
individuals (Phillips & Harper, 1997). Sudden death, due to heart block, is not common in 
DM1, but does occur in severe DM1 patients, as a result of extreme sinus bradycardia or 
tachyarrhythmia, necessitating the use of pacemakers and implantable defibrillators by 
these patients (Colleran et al., 1997). There is extensive evidence for CNS involvement in 
DM1. Cognitive impairment / mental retardation, specific patterns of psychological 
dysfunction and personality traits, are widely recognized features of congenital and juvenile 
DM1 affected patients. In addition to the above, DM1 patients develop CNS white matter 
and cerebral blood flow abnormalities (Ogata et al., 1998). Central hypersomnia, another 
recognized CNS effect of DM1, appears to occur in adulthood. Excessive daytime sleepiness 
is very common and in some cases very disabling. Apathy, epilepsy, stroke and 
parkinsonism are rarely observed in adult DM1 patients, but are fairly common in 
congenitally affected patients (Rubinsztein et al., 1997). Posterior capsular, iridescent, 
multicoloured opacities are regularly seen in DM1 patients. Cataracts can be detected in 
DM1 patients at a very early stage in the course of the disease by slit-lamp examination. 
When vision is significantly impaired, surgical intervention is required (Klesert et al., 2000). 
Irritable bowel-like symptoms such as constipation, diarrhea, colicky abdominal pain and 
pseudo-obstruction are extremely common in DM1. The upper gastrointestinal tract is 
affected in later stages of the disease and can cause dysphagia and aspiration resulting in 
serious chest infections that can cause morbidity and mortality of DM1 patients. DM1 
patients display a large variety of endocrine abnormalities. Testicular failure, 
hypotestosteronism and oligospermia are associated with the reduced fertility of these 
patients. Laboratory observations have also shown a reduction in the serum levels of IgG 
and IgM and as a result, hypogammaglobulinemia can affect these patients. Insulin 
resistance is also seen in DM1 patients, but even in severe cases, type 2 diabetes clinical 
symptoms are not linked with the disease, whilst recent evidence supports that there is 
alteration in the normal functioning of the insulin receptor (Moxley et al., 1984).  
DM1 is caused by an unstable expansion of CTG repeats in the 3′-untranslated region (3′ 
UTR) of the dystrophia myotonica protein kinase (DMPK) gene on chromosome 19q13.3 
(Aslanidis et al., 1992; Brook et al., 1992; Davies et al., 1983). The number of CTG repeats is 
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in the range of 5–35 in the normal population and increases to between 50 and several 
thousand in DM1 patients. The variation in the number of CTG repeats is closely related to 
the phenomenon of 'anticipation': The number of CTG repeats can increase through 
successive generations, due to mitotic and meiotic instabilities (Martorell et al., 1999; 
Monckton et al., 1995). Interesting is also the fact that DM1 patients might show difference 
in the number of CTG repeats from one cell to another (genetic heterogeneity). 3’UTR is a 
region that is transcribed into RNA but not translated into protein therefore the CTG 
expansion at the DM1 locus does not alter the protein sequence encoded by DMPK. The 
mechanism of pathogenesis in DM1 is different from other genetic disorders. Three different 
mechanisms of pathogenesis have been proposed to explain how repeat expansions in the 
DMPK gene result in DM1 (Tapscott & Thornton, 2001): 
i. The mutant RNA accumulates in discrete foci in the cell nucleus rather than being 
transported to the cytoplasm (Davis et al., 1997; Taneja et al., 1995), where translation of 
mRNA into protein normally takes place. According to experimental evidence this 
causes deficiency in the production of DMPK (DMPK Haploinsufficiency) (Jansen et al., 
1996; Reddy et al., 1996).  
ii. The second mechanism of pathogenesis, involves the disruption of the expression and 
function of DMPK neighboring genes. Scientific evidence showed that the expanded 
CTG repeats interfere with the nucleosome assembly and therefore on the total 
chromatin structure. This process disrupts and prevents the binding of necessary 
factors for the expression of neighboring genes (Klesert et al., 1997; Wang & Griffith, 
1995; Westerlaken et al., 2003). 
iii. Lastly, evidence suggests that the molecular pathogenesis of DM1 is to a great extent 
due to the downstream effects of the retention of the mutant DMPK transcripts in the 
nucleus. Some of these include the inhibition of myogenesis and the defective splicing 
of cellular RNA molecules (Mankodi et al., 2000; Miller et al., 2000; Timchenko et al., 
1996). 
This book chapter will focus mainly on the pathology which arises from nuclear RNA 
retention and the therapeutic approaches against it. The correlation between the CTG repeat 
size and the severity of the disease, suggests that the repeats represent the major cause of 
DM1 pathogenesis. After investigations of the mutant DMPK transcripts, it was found that 
these form nuclear foci that are enclosed within the nucleus of the affected cells (Amack & 
Mahadevan, 2001; Taneja et al., 1995). Moreover, it was postulated that these nuclear foci 
might contribute to DM1 pathogenesis, perhaps by disrupting the transport of mRNA from 
DMPK and/or other genes to the cytoplasm (Alwazzan et al., 1999; Klesert et al., 1997; Otten 
& Tapscott, 1995; Taneja et al., 1995). Further on, cell models expressing the CTG repeat 
expansion, showed also nuclear localization of mutant RNA foci and extended myogenic 
defects (Amack & Mahadevan, 2004). These nuclear RNA foci were also shown to interact 
with nuclear RNA binding proteins and subsequently alter the regulation or localization 
(Fardaei et al., 2002; Philips et al., 1998). Mutant DMPK RNA foci were found to interact 
with the CUG-binding protein (Timchenko et al., 1996) and three different forms of the 
muscleblind binding protein (MBNL) (Ho et al., 2005). Scientific evidence, using knockout 
MBNL or CUGBP animal models revealed similarities to the DM1 pathophysiology, 
including cardiac, endocrine system and muscle abnormalities (Kanadia et al., 2003; Kanadia 
et al., 2003; Roberts et al., 1997).  
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2. RNA pathogenesis 
2.1 RNA nuclear retention 
Mutant DMPK alleles are transcribed in the nucleus to produce RNA molecules containing 
expanded CUG repeats. The expanded CUG transcript folds back on itself to form stable 
duplex hairpin structures. Napierala and Kryzosiak provided evidence that hairpins indeed 
exist in the DMPK RNA fragments containing 11–49 CUG repeats and that the stability of 
these structures increases with the repeat length (Napierala & Krzyzosiak, 1997). Koch and 
Leffert, generated secondary structures of partial and full-length DMPK mRNAs carrying 
variable numbers of CUG triplet repeats (up to 500) (Koch & Leffert, 1998). They suggested 
that CUG hairpins are the most stable structures formed and also that the DMPK mRNAs 
are sterically impeded from transport through nuclear pores, by giant hairpins or hairpin 
clusters formed by CUG repeats above a limit size (44 or less) (Koch & Leffert, 1998). Further 
thermal melting and nuclease mapping studies indicated that CUG repeats form highly 
stable hairpins (Tian et al., 2000). Michalowski et al., used electron microscopy to provide 
the first visual evidence that the DMPK mRNA expansion forms an RNA hairpin structure 
(Michalowski et al., 1999). Visualization of large RNAs containing up to 130 CUG repeats 
revealed perfect double-stranded RNA segments whose lengths were that expected for 
duplex RNA (Michalowski et al., 1999). The duplex segments were highly stable, since the 
hairpin structures reformed rapidly during the electron microscopy mounting procedures 
when the RNAs were boiled and quickly cooled, even under low salt conditions 
(Michalowski et al., 1999). 
RNA harboring CUG repeat expansion impose dominant-negative effects by aberrantly 
interacting and recruiting RNA-binding proteins thus leading to nuclear retention of the 
mutant transcript and the formation of ribonuclear inclusions known as RNA foci. Taneja et 
al., used fluorochrome-conjugated and digoxigenin-conjugated oligonucleotide probes to 
analyze the intracellular localization of DMPK transcripts in fibroblasts derived from DM 
patients and normal individuals and showed a striking difference in the nuclear distribution 
of the DMPK transcripts, a difference that was verified in a muscle biopsy from an affected 
individual (Taneja et al., 1995). Davis et al., generated “myoblasts” by MyoD retroviral 
infection of DM1 fibroblast lines and showed that mutant DMPK transcripts were abundant 
in myoblasts, but could not contribute to kinase production, as the transcripts were 
quantitatively retained within myoblast nuclei (Davis et al., 1997). Terminally differentiated 
myoblasts contained no cytoplasmic mutant transcripts; instead, they formed stable, long-
lived clusters that were tightly linked to the nuclear matrix (Davis et al., 1997). Myoblasts 
and myotubes isolated from patients with congenital myotonic dystrophy (CDM1) also 
showed abnormal retention of mutant RNA in nuclear foci (Furling et al., 2001).  
2.2 CUG binding protein 1 (CUGBP1) 
Proteins of the CELF family are a group of proteins extensively studied for their implication 
in DM1 pathogenesis. CELF (CUGBP and ETR-3-like factors) proteins are a family of 
structurally related RNA-binding proteins involved in various aspects of RNA processing 
including alternative splicing, translation and mRNA stability. The first member of the 
CELF family, CELF1/CUGBP1, was identified in investigating the molecular mechanisms of 
DM1 (Gallo & Spickett, 2010). Timchenko et al. reported that CUG binding protein 1 
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(CUGBP1) binds specifically to CUG triplet repeated sequences (Timchenko et al., 1996; 
Timchenko et al., 1996). Electron microscopy studies showed that CUGBP1 is primarily a 
single-stranded RNA-binding protein that has a binding preference for CUG-rich RNA 
elements but not double-stranded CUG hairpins (Michalowski et al., 1999). Moreover, 
CUGBP1 was visualized to localize to the base of the RNA hairpin and not along the stem 
(Michalowski et al., 1999). In a yeast three-hybrid system CUGBP1 was found to associate 
with long CUG trinucleotide repeats ((CUG)(11)(CUG)(12)), but not with short repeats 
((CUG)(12)) (Takahashi et al., 2000). However, using a combination of indirect 
immunofluorescence to detect endogenous proteins and overexpression of proteins with 
green fluorescent protein (GFP) tags it has been shown that CUGBP1 does not co-localise 
with triplet repeat foci in DM1 fibroblast cell lines (Fardaei et al., 2001). 
Experiments in tissue culture and analysis of DM1 patients demonstrated that RNA CUG 
repeats directly affect expression and activity of CUGBP1 in DM1 myoblasts, heart, and 
skeletal muscle tissues (Timchenko et al., 2001). Specifically, the formation of CUGBP1 · 
CUG RNA complexes is accompanied by increased CUGBP1 protein stability and 
subsequent elevation of CUGBP1 (Timchenko et al., 2001). Furthermore, nuclear CUGBP1 
levels have been found increased in DM1 patients, compared to normal subjects (Timchenko 
et al., 2001). These observations suggest that abnormal activation of CUGBP1 is related to 
DM1 pathogenesis. Furthermore, in a transgenic mice model, overexpression of CUGBP1 in 
heart and skeletal muscle, produced DM1-like symptoms such as central nuclei, chains of 
nuclei, centralized nicotinamide adenine dinucleotide (NADH) reactivity and mis-splicing 
(Ho et al., 2005). De Haro et al., generated a Drosophila model of DM1 that showed 
degenerative phenotypes in muscle and eye tissue and key histopathological features of the 
DM1, including accumulation of the expanded transcripts in nuclear foci (de Haro et al., 
2006). Using this model they showed that by increasing the levels of CUGBP1 degeneration 
is deteriorated even though CUGBP1 distribution is not altered by the expression of the 
expanded triplet repeat (de Haro et al., 2006). Wang et al., generated an inducible and heart-
specific DM1 mouse model expressing expanded CUG RNA in the context of DMPK 3' UTR 
that recapitulated pathological and molecular features of DM1 including dilated 
cardiomyopathy, arrhythmias, systolic and diastolic dysfunction, and mis-regulated 
alternative splicing (Wang et al., 2007). Combined in situ hybridization and 
immunofluorescent staining for CUGBP1 protein expressed in heart, showed increased 
protein levels specifically in nuclei containing foci of CUG repeat RNA (Wang et al., 2007).  
Although the molecular mechanisms for increased CUGBP1 is not completely understood, 
Kuyumcu-Martinez et al. reported that the expression of mutant DMPK-CUG-repeat RNA 
results in hyperphosphorylation and stabilization of CUGBP1 through the inappropriate 
activation of the protein kinase C (PKC) pathway, in DM1 tissues, cells, and a DM1 mouse 
model (Kuyumcu-Martinez et al., 2007). Experiments performed in C2C12 mouse cell line 
showed that expression of a mutant DMPK 3'-UTR containing 960 CUG repeats is sufficient 
to increase expression and stability of an mRNA encoding the potent proinflammatory 
cytokine, tumor necrosis factor (TNF), which was found elevated in DM1 patients serum 
(Mammarella et al., 2002; Zhang et al., 2008). Moreover, activation of the protein kinase C 
(PKC) pathway also stabilized the TNF transcript. These results suggest that the elevated 
serum TNF seen in DM1 patients may be derived from muscle where it is induced by 
expression of toxic DMPK RNA (Zhang et al., 2008). In a more recent study, Koshelev et al. 
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used tetracycline-inducible CUGBP1 and heart-specific reverse tetracycline trans-activator 
transgenes in order to express human CUGBP1 in adult mouse heart (Koshelev et al., 2010). 
Up-regulation of CUGBP1 was sufficient to reproduce molecular, histopathological and 
functional changes observed in DM1 patients and in a DM1 mouse model thus supporting a 
role for CUGBP1 up-regulation in DM1 pathogenesis (Koshelev et al., 2010). In another 
mouse model, Ward et al. overexpressed CUGBP1 and showed that mice reproduced 
molecular and physiological defects of DM1 tissue, suggesting that CUGBP1 has a major 
role in DM1 skeletal muscle pathogenesis (Ward et al., 2010). 
2.3 Muscleblind (MBNL) family proteins 
Muscleblind (MBNL) family proteins, initially identified by Miller et al. were selectively 
associated with CUG repeat expansions and named as triplet repeat expansion (EXP) 
double-stranded (ds) RNA-binding proteins (Miller et al., 2000). Human EXP proteins are 
found to be orthologous to the Drosophila MBNL proteins, which are required for terminal 
differentiation of photoreceptors and muscle cells (Artero et al., 1998; Begemann et al., 1997). 
The alternative splicing factor MBNL1 binds to pyrimidine-rich pre-mRNAs containing 
YGCY motifs and promotes either the inclusion or the exclusion of alternative exons 
depending on the 5′ or 3′ localization of cis-regulatory elements (Goers et al., 2010). All three 
isoforms of MBNL family proteins (MBNL/MBNL1, MBLL/MBNL2 and MBXL/MBNL3) 
co-localize with the nuclear mutant RNA foci in DM1 cells, presumably diverting them from 
their normal cellular functions (Wojciechowska & Krzyzosiak, 2011). The biological 
significance of the interaction between mutant RNA and MBNL-family proteins has been 
manifested through the disruption of alternative splicing which is a characteristic feature of 
DM1 pathogenesis (Wojciechowska & Krzyzosiak, 2011). Fardaei et al. investigated for the 
first time the localization of MBNL (EXP) protein with mutant DMPK transcripts (Fardaei et 
al., 2001). Using indirect immunofluorescence to detect endogenous proteins and 
overexpression of GFP-tagged MBNL, they showed that MBNL forms foci in DM1 fibroblast 
cell lines and co-localises with the foci of expanded repeat transcripts in the nuclei of DM1 
cells (Fardaei et al., 2001). The binding of MBNL1 with expanded CUG repeats was further 
verified in DM1 muscle biopsy tissues (Mankodi et al., 2003) and in a yeast three-hybrid 
system (Kino et al., 2004). Overexpression of MBNL1 in vivo using a recombinant adeno-
associated viral vector rescued disease-associated muscle myotonia and aberrant splicing of 
specific gene transcripts, characteristic of DM1 skeletal muscle supporting the hypothesis 
that loss of MBNL1 activity is a primary pathogenic event in the development of the disease 
(Kanadia et al., 2006). 
Analysis of the expression pattern of the mouse Mbnl1, Mbnl2, Mbnl3 and Dmpk genes 
during embryonic development revealed a striking overlap between the expression of Dmpk 
and the Mbnl genes during development of the limbs, nervous system and various muscles, 
including the diaphragm and tongue (Kanadia et al., 2003). In 2003, Kanadia et al. generated 
the first MBNL knockout mouse model for DM1 (Kanadia et al., 2003). The disruption of the 
mouse Mbnl1 gene led to muscle, eye and RNA splicing abnormalities which are 
characteristics of DM1 disease (Kanadia et al., 2003). Examination of DM1 post-mortem 
brain tissue by FISH indicated that the mutant DMPK mRNA is widely expressed in cortical 
and subcortical neurons and accumulated in discrete foci within neuronal nuclei (Jiang et al., 
2004). Moreover, MBNL family proteins were recruited into the RNA foci and a subset of 
www.intechopen.com
 
Myotonic Dystrophy Type 1: Focus on the RNA Pathology and Therapy 
 
505 
neuronal pre-mRNAs showed abnormal regulation of alternative splicing suggesting that 
central nervous system impairment in DM1 may result from a deleterious gain-of-function 
by mutant DMPK mRNA (Jiang et al., 2004). In 2005, Mankodi et al. provided evidence that 
accumulation of expanded CUG repeats in nuclear foci was associated with sequestration of 
MBNL proteins and abnormal regulation of alternative splicing in cardiac muscle tissue 
from DM1 patients (Mankodi et al., 2005).  
In a Drosophila model of DM1 expressing CTG repeats in the 3′-UTR of a marker gene CUG 
repeats form discrete ribonuclear foci in muscle cells that co-localize with MBNL (Houseley 
et al., 2005). Moreover, MBNL was also revealed as having a previously unrecognized role 
in stabilizing CUG transcripts (Houseley et al., 2005). In another Drosophila model of DM1 
that shows degenerative phenotypes in muscle and eye tissue as well as key 
histopathological features of the DM1, including accumulation of the expanded transcripts 
in nuclear foci and their co-localization with MBNL1 protein, reduced levels of MBNL1 
aggravate the muscle and eye phenotypes of DM1 flies whereas MBNL1 overexpression 
suppresses the degenerative phenotypes (de Haro et al., 2006). Mbnl2-deficient mice 
developed myotonia, skeletal muscle pathology consistent with human DM1 and defective 
CLCN1 mRNA splicing in skeletal muscle, supporting the hypothesis that MBNL proteins 
and specifically MBNL2 contribute to the pathogenesis of human DM1 (Hao et al., 2008). 
These results are consistent with the notion that Mbnl1 deficiency alone is not sufficient to 
fully replicate the human DM1 phenotype (Kanadia et al., 2003). An additional mouse DM1 
model with inducible and skeletal muscle-specific expression of 960 CTG repeats in the 
context of DMPK exon 15 recapitulated many findings associated with DM1 skeletal muscle, 
such as nuclear foci with MBNL1 protein co-localization, mis-splicing, myotonia, 
characteristic histological abnormalities, and increased CUGBP1 protein levels (Orengo et 
al., 2008). Importantly, this DM1 mouse model exhibited severe muscle wasting, which has 
not been reported previously in models in which MBNL1 depletion was the main feature 
(Orengo et al., 2008). More recently, Machuca-Tzili et al. generated an mbnl2 knockdown 
zebrafish model, which exhibits features of DM (Machuca-Tzili et al., 2011). They showed 
that loss of zebrafish mbnl2 function causes muscle defects and splicing abnormalities of 
clcn1 and tnnt2 transcripts, similar to those observed in DM1 patients (Machuca-Tzili et al., 
2011).  
Wheeler et al., showed that CUG expanded RNA is also expressed in subsynaptic nuclei of 
muscle fibers and in motor neurons in DM1 patients, causing sequestration of MBNL1 
protein in both locations (Wheeler et al., 2007). Additionally, in a transgenic mouse model, 
expression of CUG expanded RNA at high levels in extrajunctional nuclei replicates many 
features of DM1, including myotonia, spliceopathy, internal nuclei, ring fibers, and 
sarcoplasmic masses, but the toxic RNA is poorly expressed in subsynaptic nuclei and mice 
fail to develop denervation-like features of DM1 myopathology (Wheeler et al., 2007). These 
findings suggest that subsynaptic nuclei and motor neurons are at risk for DM1-induced 
mis-splicing, which may affect function or stability of the neuromuscular junction (Wheeler 
et al., 2007). MBNL1 protein was also found in the human brain, and consists of several 
isoforms, as shown by RT-PCR and sequencing. In the brain tissue of DM1 patients, a fetal 
isoform of MBNL1 was found overexpressed (Dhaenens et al., 2008). The expression of this 
fetal isoform can also be reproduced by the ectopic expression of long CUG repeats in vitro 
(Dhaenens et al., 2008). 
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2.4 Mis-regulation of alternative splicing 
At the molecular level, one of the best-characterized trans-dominant effects induced by the 
mutant DMPK RNAs in DM1 is the mis-regulation of alternative splicing of a subset of pre-
mRNAs. Alternative splicing is a process by which the exons of the transcribed pre-mRNA 
are reconnected in multiple ways to give rise to different mRNAs which are in turn 
translated into different protein isoforms. To date, more than twenty transcripts have been 
found to be mis-spliced in different tissues of DM1 patients (Klein et al., 2011).  
2.4.1 CUGBP1 and MBNL1 significance in alternative splicing mis-regulation  
Mis-splicing events observed in DM1 result from an inappropriate regulation of alternative 
splicing due to altered activities of splicing regulators such as CUGBP1 and MBNL1. The 
biological significance of CUGBP1 overexpression and MBNL family proteins sequestration 
to nuclear RNA foci has been manifested through the disruption of alternative splicing, 
which is a characteristic feature of DM1 pathogenesis. Muscle wasting and weakness, heart 
problems and insulin resistance are associated with aberrant alternative splicing of a range 
of pre-mRNAs. 
2.4.1.1 Cardiac troponin T (cTNT)  
The first mis-regulation of alternative splicing described in DM1 was the abnormal inclusion 
of exon 5 in cardiac troponin T (cTNT) in cardiac muscle (Philips et al., 1998). CUGBP1 was 
found to bind to the human cTNT pre–mRNA and regulate its alternative splicing. Splicing 
of cTNT was disrupted in DM1 striated muscle and in normal cells expressing CUG 
expanded RNAs (Philips et al., 1998). Transgenic mice with a targeted deletion of Mbnl1 
exon 3 (E3) (Mbnl1ΔE3/ΔE3) in adult heart showed abnormal retention of the cTNT “fetal” 
exon 5, as was observed in DM1 (Kanadia et al., 2003; Philips et al., 1998). Ho et al., involved 
for the first time all three MBNL family members with mis-regulation of alternative splicing 
in DM1 (Ho et al., 2004). MBNL proteins were found to act antagonistically to CELF proteins 
on the human and chicken cTNT pre-mRNAs (Ho et al., 2004). MBNL1 binds a common 
motif near the human and chicken cTNT alternative exons within intronic regions, which 
appear to be single stranded (Ho et al., 2004). Furthermore, CELF and MBNL proteins bind 
to distinct cis-elements and minigenes containing CELF- or MBNL-binding site mutations 
thus showing that regulation by one family does not require responsiveness to the other (Ho 
et al., 2004). However, modified cTNT minigenes made nonresponsive to the trans-dominant 
effects of CUG repeat RNA still respond to MBNL depletion, suggesting that CUG repeat 
RNA affects splicing by a mechanism more complex than MBNL depletion alone (Ho et al., 
2004). 
2.4.1.2 Insulin receptor (IR) 
Three years after the discovery of the first pre-mRNA that is mis-spliced in DM1, Savkur et 
al., described the second pre-mRNA that undergoes mis-regulation of alternative splicing in 
DM1 skeletal tissue (Savkur et al., 2001). Alternative splicing of the insulin receptor (IR) pre-
mRNA was aberrantly regulated in DM1, resulting in predominant expression of the lower-
signaling non-muscle isoform (IR-A) of the receptor (Savkur et al., 2001). IR-A also 
predominates in DM1 skeletal muscle cultures, which exhibit a reduced responsiveness to 
the metabolic effects of insulin (Savkur et al., 2001). Furthermore, the aberrant regulation of 
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IR alternative splicing was reproduced in normal cells by the expression of CUG-repeat 
RNA (Savkur et al., 2001). Additionally, overexpression of CUGBP1 also induced a switch to 
IR-A in normal cells (Savkur et al., 2001). The CUGBP1 protein mediates this switch through 
an intronic element located upstream of the alternatively spliced exon 11, and specifically 
binds within this element in vitro (Savkur et al., 2001). The research group suggested a 
model in which increased expression CUGBP1 splicing regulator contributes to insulin 
resistance observed in DM1 by affecting IR alternative splicing (Savkur et al., 2001). 
In addition to CUGBP1, IR alternative splicing was found to be regulated by MBNL1 (Ho et 
al., 2004). Down-regulation of MBNL1 and MBNL2 in normal myoblasts resulted in 
abnormal splice pattern observed in DM1 (Dansithong et al., 2005). Moreover, CUGBP1 was 
found to regulate the equilibrium of splice site selection by antagonizing the facilitatory 
activity of MBNL1 and MBNL2 on IR exon 11 splicing in a dose-dependent manner 
(Dansithong et al., 2005). Rescued experiments in DM1 myoblasts demonstrated that loss of 
MBNL1 function is the critical event, whereas CUGBP1 overexpression plays a secondary 
role in the aberrant alternative splicing of IR RNA in DM1 (Dansithong et al., 2005). 
Therefore, these experiments demonstrated that MBNL1 sequestration is the primary 
determinant of the IR pre-mRNA abnormal splicing in DM1 myoblasts (Dansithong et al., 
2005).  
2.4.1.3 Chloride channel - 1 (ClC-1) 
In a transgenic mouse model of DM1, the expression of expanded CUG repeats reduced the 
transmembrane chloride conductance to an extent sufficient to account for myotonia 
(Mankodi et al., 2002). These mice showed abnormal splicing of pre-mRNA encoding 
chloride channel – 1 (ClC-1), the main chloride channel in skeletal muscle, resulting in loss 
of ClC-1 protein from the surface membrane (Mankodi et al., 2002). Furthermore, the 
induction of abnormal ClC-1 splicing, the corresponding loss of ClC-1 protein from the 
muscle membrane, and the development of myotonia were tightly correlated with the level 
of expanded CUG repeats in different transgenic lines (Mankodi et al., 2002). Additional to 
the mice models, similar effects on CLC-1 splicing and protein accumulation in muscle 
tissue from patients with DM1 (Mankodi et al., 2002). These findings suggest that mis-
regulation of ClC-1 pre-mRNA alternative splicing is an important factor that leads to 
myotonia observed in DM1 patients. In an additional study, loss of ClC-1 mRNA and 
protein due to aberrant splicing of the ClC-1 pre-mRNA was detected in DM1 skeletal 
muscle tissue (Charlet et al., 2002). Specifically, the majority of ClC-1 mRNAs contained 
premature termination codons due to retention of intron 2 or inclusion of two novel exons 
between exons 6 and 7 (Charlet et al., 2002). CUGBP1, which is found elevated in DM1 
striated muscle, bound to the ClC-1 pre-mRNA, and overexpression of CUGBP1 in normal 
cells reproduced the aberrant pattern of ClC-1 splicing observed in DM1 skeletal muscle 
(Charlet et al., 2002). In particular, CUGBP1 induced retention of intron 2 by binding to a 
U/G-rich motif common to other pre-mRNA targets of CUGBP1 thus suggesting that 
increased CUGBP1 activity in DM1 causes aberrant regulation of ClC-1 alternative splicing 
(Charlet et al., 2002).  
2.4.1.4 Tau  
Tau protein belongs to the family of microtubule-associated proteins whose transcript 
undergoes complex regulated splicing in the mammalian nervous system. They are 
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essentially expressed in neurons where their essential function is to regulate the microtubule 
network. In the adult human central nervous system, alternative splicing of exons 2, 3 and 
10 of the single tau gene transcript gives six tau isoforms (Sergeant et al., 2001). The tau 
isoforms aggregated in DM1 brain lesions consists mainly of the shortest human tau isoform 
suggesting that the (CTG)n expansion is altering the processing of tau pre-mRNA splicing 
and gives rise to symptoms such as dementia (Sergeant et al., 2001).  
2.4.1.5 Myotubularin-related 1 (MTMR1) 
The myotubularin-related 1 (MTMR1) gene belongs to a highly conserved family of 
phosphatases with at least 11 isoforms in humans (Buj-Bello et al., 2002). One of the 
transcripts resulting from MTMR1 alternative slicing is muscle-specific and is induced 
during myogenesis both in vitro and in vivo, and represents the major isoform in adult 
skeletal muscle (Buj-Bello et al., 2002). MTMR1 splicing pattern was found strikingly altered 
in cultured muscle cells, in skeletal muscle from patients with congenital myotonic 
dystrophy (CDM1) and in DM1 muscle biopsies (Buj-Bello et al., 2002; Santoro et al., 2010). 
2.4.1.6 Ryanodine receptor 1 (RyR1) and sarcoplasmic/endoplasmic reticulum Ca2+-
ATPase (SERCA) 1 or 2 
Ryanodine receptor 1 (RyR1) and sarcoplasmic/endoplasmic reticulum Ca2+-ATPase 
(SERCA) 1 or 2 which are the main sarcoplasmic reticulum regulators of intracellular Ca2+ 
homeostasis in skeletal muscle cells (Kimura et al., 2005). The fetal variants, ASI(-) of RyR1 
which lacks residue 3481-3485, and SERCA1b which differs at the C-terminal were found 
significantly increased in skeletal muscles from DM1 patients and a transgenic mouse model 
of DM1 thus suggesting that aberrant splicing of RyR1 and SERCA1 mRNAs might 
contribute to impaired Ca2+ homeostasis in DM1 muscle (Kimura et al., 2005). 
2.4.1.7 Myocyte enhancer factor 2 (Mef2)  
MBNL3 regulates the splicing pattern of the muscle transcription factor myocyte enhancer 
factor 2 (Mef2) (Lee et al., 2010). MBNL3 antagonizes muscle differentiation by disrupting 
the expression of (+)β isoform of Mef2D which is transcriptionally more active (Lee et al., 
2010). Using a DM1 cell culture model and DM1 patient tissue, they provided evidence that 
expression of CUG expanded RNAs can lead to an increase in MBNL3 expression 
accompanied by a decrease in Mef2D β-exon splicing (Lee et al., 2010). These studies suggest 
that an increase in MBNL3 activity may play a role in the skeletal muscle degeneration 
experienced by DM1 patients (Lee et al., 2010). 
2.4.1.8 Bridging integrator-1 (BIN1)  
Bridging integrator-1 (BIN1) is a myc box-dependent-interacting protein involved in tubular 
invaginations of membranes and is required for the biogenesis of muscle T tubules, which 
are specialized skeletal muscle membrane structures essential for excitation-contraction 
coupling (Fugier et al., 2011). Mutations in the BIN1 gene cause centronuclear myopathy, 
which shares some histopathological features with myotonic dystrophy (Jungbluth et al., 
2008). BIN1’s function is regulated by alternative splicing which was found altered in 
skeletal muscle samples of people with CDM1 and DM1 (Fugier et al., 2011). Particularly, 
MBNL1 was detected to bind the BIN1 pre-mRNA and regulate the alternative splicing of 
the exon 11 (Fugier et al., 2011). Sequestration of MBNL1 by expanded CUG repeats in DM1 
patients resulted in expression of an inactive form of BIN1 lacking phosphatidylinositol 5-
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phosphate-binding and membrane-tubulating activities (Fugier et al., 2011). Consistent with 
a defect of BIN1, muscle T tubules found altered in DM1 patients, and membrane structures 
were restored upon expression of the normal splicing form of BIN1 in muscle cells of such 
individuals (Fugier et al., 2011). Finally, reproducing BIN1 splicing alteration in mice was 
sufficient to promote T tubule alterations and muscle weakness, a predominant feature of 
DM1 (Fugier et al., 2011). 
2.4.1.9 Myomesin 1 (MYOM1) 
Myomesin 1 (MYOM1) is a constituent of the M band of the sacromere which is the basic 
unit of a muscle (Lange et al., 2005). The fact that MYOM1 is a structural constituent of 
muscle suggests that it could be involved in muscle impairment in patients with DM1. 
Koebis et al. used exon array and identified aberrant inclusion of MYOM1 exon 17a as a 
novel splicing abnormality in DM1 muscle (Koebis et al., 2011). A cellular splicing assay 
using a MYOM1 minigene revealed that MBNL and CELF family proteins function as trans-
acting factors in the alternative splicing of MYOM1 exon 17a (Koebis et al., 2011). Expression 
of expanded CUG repeat impeded MBNL1 activity but did not affect CUGBP1 activity on 
the splicing of MYOM1 minigene (Koebis et al., 2011). These results suggested that the 
downregulation of MBNL proteins should lead to the abnormal splicing of MYOM1 exon 
17a in DM1 muscle (Koebis et al., 2011). 
2.5 Myogenic defects 
DM1-associated molecular events, such as abberant recruitment of RNA-binding proteins 
into ribonuclear foci and mis-splicing, could eventually provoke alterations in global cell 
function. Notably, a critical disorder of DM1 that distinguishes it from other muscular 
dystrophies is the defects observed in muscle differentiation. Fetal muscle development is 
affected in fetuses with congenital myotonic dystrophy whereas muscle regeneration is 
compromised in adult patients (Amack & Mahadevan, 2004).  
Initial experiments performed in the mouse myoblast cell line C2C12 showed that 
overexpression of the mouse dmpk gene leads to markedly inhibition of both fusion and 
terminal differentiation of the cell line (Okoli et al., 1998). Further experiments performed 
on C2C12 cell line showed that overexpression of human DMPK mRNA caused a marked 
inhibition of terminal differentiation accompanied by a reduction of myogenin mRNA 
levels (Sabourin et al., 1997). These results suggest that overexpression of the DMPK 3'-
UTR may interfere with the expression of muscle-specific mRNAs leading to a delay in 
muscle terminal differentiation (Sabourin et al., 1997). Amack et al. used reporter assays 
to provide unambiguous evidence that the expression of the mutant DMPK 3′-UTR mRNA 
with (CUG)200 selectively inhibited myogenic differentiation of C2C12 myoblasts (Amack 
et al., 1999). In agreement, overexpression of DMPK 3'-UTR including either wild-type or 
expanded CTG repeats resulted in aberrant and delayed muscle development in fetal 
transgenic mice and displayed muscle atrophy at 3 months of age. Moreover, primary 
myoblast cultures from both wild-type and expanded CTG repeat mice showed reduced 
fusion potential with greater reduction observed in the expanded repeat cultures 
(Storbeck et al., 2004). Interestingly, the differentiation defect was confirmed in muscle 
cell cultures derived from DM1 fetuses and patients (Furling et al., 2001; Timchenko et al., 
2001).  
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Molecular studies have begun to uncover the effect of the mutant DMPK mRNA on 
myogenesis inhibition. Various studies implicate CUGBP1 protein with myogenic 
impairment in DM1, since it is a key regulator of translation of proteins that are involved in 
muscle development and differentiation. Timchenko et al. reported that cultured myoblasts 
isolated from DM1 patients failed to permanently withdraw from the cell cycle when 
stimulated to differentiate (Timchenko et al., 2001). Skeletal muscle cells from DM1 patients 
failed to induce cytoplasmic levels of CUGBP1, while normal differentiated cells accumulate 
CUGBP1 in the cytoplasm (Timchenko et al., 2001). In normal cells, CUGBP1 up-regulates 
p21 translation during differentiation by binding to a GC-rich sequence located within the 5' 
region of p21 mRNA (Timchenko et al., 2001). DM1 cultured cells failed to accumulate 
CUGBP1 in the cytoplasm thus leading to a significant reduction of p21 and to alterations of 
other proteins responsible for the cell cycle withdrawal (Timchenko et al., 2001). In normal 
cells, activity of cdk4 declines during differentiation, whereas in DM1 cells cdk4 is highly 
active during all stages of differentiation (Timchenko et al., 2001). Furthermore, DM1 cells 
do not form Rb/E2F repressor complexes that are abundant in differentiated cells from 
normal individuals (Timchenko et al., 2001). These data provide evidence for an impaired 
cell cycle withdrawal in DM1 muscle cells and suggest that alterations in the CUGBP1 
activity causes disruption of p21-dependent control of cell cycle arrest (Timchenko et al., 
2001). Another study showed that CUGBP1 is phosphorylated by different kinases during 
myoblast proliferation and differentiation and that phosphorylation of CUGBP1 at different 
sites directs CUGBP1 to different mRNA targets (Salisbury et al., 2008). Specifically, Akt kinase 
and cyclinD3-cdk4/6 phosphorylate CUGBP1 during proliferation and differentiation, 
respectively (Salisbury et al., 2008). Cyclin D3-cdk4-mediated phosphorylation of CUGBP1 
increases the interactions of CUGBP1 with eIF2 during normal myogenesis, a pathway found 
to be reduced in DM1 cells (Salisbury et al., 2008). Moreover, ectopic expression of cyclin D3 
in DM1 cells enhances fusion of DM1 myoblasts and leads to the correction of differentiation 
(Salisbury et al., 2008). A more recent study, showed that human skeletal muscle satellite 
cells isolated from fetal congenital DM1 patients bearing large CTG expansions (>3000) 
secrete prostaglandin E2 (PGE(2)) that inhibits the fusion of normal myoblasts in culture by 
decreasing the intracellular levels of calcium (Beaulieu et al., 2011). Authors suggest that the 
delay in muscle maturation observed in congenital DM1 patients may result, at least in part, 
from an altered autocrine mechanism (Beaulieu et al., 2011).  
3. Therapeutic approaches for DM1 
3.1 Restoring MBNL1 and CUGBP1 protein activity 
It is widely accepted that MBNL and CUGBP play a major role in the pathogenesis of DM1 
and are therefore targets for the reversal of the defective splicing and subsequent alleviation 
of symptoms in the disease. MBNL activity is compromised due to its sequestration in RNA 
foci. Therefore an approach to increase its expression levels and hence its activity could 
serve as a potential route for restoring alternative splicing. Kanadia et al. used intramuscular 
injection with an AAV (adeno-associated virus) expressing MBNL1 protein in a transgenic 
mouse model of DM1. This transgenic mouse model carries the human skeletal α-actin (HSA) 
gene modified by insertion of 250 CTG repeats within the 3’ untranslated region. These mice 
develop severe myotonia and dystrophic muscle features characteristic of DM1 disease. 
Overexpression of MBNL1 saturated the expanded CUG binding sites of the mutant DMPK 
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transcripts and free MBNL1 was able to cause the reversal of muscle hyperexcitability, 
myotonia and spliceopathy (Kanadia et al., 2006). These results, demonstrated that the 
elevated expression of MBNL1 alone was sufficient to rescue myotonia, a key pathological 
feature of DM1, and aberrant splicing of specific gene transcripts, characteristic of the DM1 
skeletal muscle. In a parallel study, de Haro et al. used a Drosophila model of DM1 expressing 
mRNA transcripts containing 480 CUG repeats, which accumulate in nuclear foci and show 
degenerative phenotypes in muscle (muscle wasting) and eye tissue (disorganization and 
fusion of the ommatidia as well as loss and duplication of inter-ommatidial bristles) as well as 
other key histopathological features of DM1. Furthermore, this DM1 model shows altered 
levels of MBNL1 and CUGBP1, as observed in DM1 pathogenesis. Overexpression of MBNl1 
in this DM1 model showed to suppress the muscle and eye phenotypes of DM1. 
Interestingly, expanded RNA transcripts that accumulated in nuclear foci within muscle 
cells were decreased in flies expressing the mutant RNA transcripts that also overexpress 
MBNL1 (de Haro et al., 2006).  
CUGBP1 has been shown to be up-regulated in DM1 as a result of PKC activation and 
subsequent CUGBP1 protein hyperphosphorylation and stabilization (Kuyumcu-Martinez 
et al., 2007). Wang et al. created a heart specific Tamoxifen-inducible mouse model 
containing 960 CTG repeats within the last exon of the DMPK. These mice exhibited high 
mortality, conduction abnormalities, and systolic and diastolic dysfunction as well as 
molecular changes seen in DM1 patients, such as increased levels of CUGBP1, colocalization 
of MBNL1 with RNA foci and reversion of splicing to embryonic patterns. Blocking of PKC 
activity, using a specific PKC inhibitor (Ro-31-8220), in this heart-specific DM1 mouse model 
ameliorated several DM1 symptoms, including cardiac conduction defects and contraction 
abnormalities (Wang et al., 2009). The inhibitor also reduced the splicing defects regulated 
by CUGBP1, but not those regulated by MBNL1, suggesting distinct roles for these proteins 
in DM1 cardiac pathogenesis (Wang et al., 2009). As previously described, DM1 mouse 
models showed elevated levels of CUGBP1 that leads to a delay of muscle development and 
differentiation. Salisbury et al. presented evidence that two signal transduction pathways 
regulate CUGBP1 activity in normal muscle and that these pathways are altered in DM1 
cells. CUGBP1 was found to be phosphorylated by different kinases, during myoblast 
proliferation and differentiation and that phosphorylation of CUGBP1 at different sites 
directs CUGBP1 to different mRNA targets. Moreover, cyclin D3-cdk4-mediated 
phosphorylation of CUGBP1 increases the interactions of CUGBP1 with eIF2 during normal 
myogenesis. Furthermore, it was found that cyclin D3-cdk4 pathway is reduced in DM1 
cells and that the normalization of cyclin D3 expression in DM1 cells leads to the correction 
of differentiation (Salisbury et al., 2008). 
Overexpression of MBNL1 and downregulation of CUGBP1 or modulation of their 
counterparts showed encouraging results towards the development of rational therapies for 
DM1. These two key proteins play a major role in the pathogenesis of the disease and any 
attempt to normalize their function will be beneficial. 
3.2 Targeting the mutant DMPK transcripts 
A promising gene therapy approach is to target the mutant DMPK transcripts. Most of the 
attempts to eliminate toxic DMPK transcripts in DM1 cells and animal models used catalytic 
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RNA (ribozymes) (Langlois et al., 2003; Phylactou et al., 1998), chemically modified 
antisense oligonucleotides (Furling et al., 2003; Mulders et al., 2009) and siRNA duplexes 
(Langlois et al., 2005).  
Ribozymes are RNA molecules that adopt a tertiary structure and function as catalysts. The 
hammerhead, hairpin and hepatitis delta virus (HDV) ribozyme motifs can be characterized 
by their ability for self-cleavage of a particular phosphodiester bond. Hammerhead 
ribozymes have the ability to suppress gene expression through specific cleavage of RNA 
molecules (Phylactou et al., 1998; Tedeschi et al., 2009). Langlois et al. designed a 
hammerhead ribozyme with significant accessibility to a specific target site within the 3’ 
UTR of the DMPK mRNA. Utilizing this system, a significant reduction of mutant and 
normal DMPK 3’ UTR transcripts was observed. Furthermore, these human DM1 myoblasts 
showed a significant reduction of nuclear RNA foci and a partial restoration of insulin 
receptor isoform B expression. This study demonstrated for the first time intracellular 
ribozyme-mediated cleavage of nuclear-retained mutant DMPK mRNAs, providing a 
potential gene therapy agent for the treatment of myotonic dystrophy (Langlois et al., 2003). 
Beside degradation of their targets, ribozymes can lead to splicing events that replace target 
RNA with embedded sequences. Group I Intron ribozymes can be characterized by their 
capacity for self-splicing by cleavage and ligation of phosphodiester bonds (Cech, 1990; 
Fiskaa & Birgisdottir, 2010). Group I intron ribozymes can be designed to act in trans by 
recognition and separation of RNA molecules in a sequence specific manner, and ligation of 
a new RNA sequence to the separated RNA molecules. In their 1998 study, Phylactou et al. 
created a group I intron ribozyme to cleave, in vitro, a DMPK RNA containing 12 repeats 
and replace them with 5 repeats. Furthermore, it was shown that similar splicing was able to 
be achieved in human cultured fibroblasts (Phylactou et al., 1998). Another promising 
approach is to target the mutant DMPK transcripts with antisense oligonucleotides. In 2003, 
Furling et al. showed that by infecting DM1 cells in culture with an adenoviral vector 
expressing an antisense RNA to the CUG repeat sequence, the mutant DMPK mRNA was 
significantly reduced. In addition, effective restoration of human DM1 myoblast functions 
such as myoblast fusion and the uptake of glucose was achieved (Furling et al., 2003). 
Furthermore, DM1 cells expressing the antisense RNA indicated a correction of CUGBP1 
expression in infected DM1 cells. Muscle differentiation and insulin resistance in DM1 were 
found to be in close proximity with the misregulation of CUGBP1 protein levels.  
Alternative approaches towards targeting the mutant DMPK transcripts in DM1, include the 
use of chemically modified antisense oligonucleotides. A recent report showed convincingly 
the therapeutic effect of 2-O-methyl phosphorothioate modified (CAG) 7 oligonucleotides in 
DM1 mouse models and in patient myoblast cultures (Mulders et al., 2009). The addition of 
2-O-methyl groups to a phosphorothioate-modified oligonucleotide confirms increased 
stability of binding and reduced nonspecific effects. Local administration of the modified 
oligonucleotide in skeletal muscle resulted in approximately 50% reduction of expanded 
DMPK RNA. As a result, RNA foci were also reduced and defective splicing corrected. 
Such findings demonstrate that a low (CUG) n RNA dosage can still be beneficial to 
patients and be an attractive therapeutic approach. Myotonia is one of the key features of 
DM1 and is associated with abnormal alternative splicing of the muscle-specific chloride 
channel (ClC-1) and reduced conductance of chloride ions in the sarcolemma. Wheeler et 
al. developed a morpholino antisense oligonucleotide targeting the 3′ splice site of ClC-1 
exon 7a and reversed the defect of ClC-1 alternative splicing in two mouse models of 
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DM1. The levels of ClC-1 mRNA and eventually protein were found to be upregulated. 
Moreover, treated mice had a fully functional chloride channel and lack myotonia 
(Wheeler et al., 2007). 
In one approach to inhibit the sequestration of MBNL1 with the expanded CUG repeats, 
Wheeler et al. used a (CAG) 25 antisense oligonucleotide morpholino. Antisense 
morpholinos are unable to cause the cleavage of their target RNAs. In vitro, these 
morpholinos were able to bind to the expanded CUG repeats forming a stable RNA-
morpholino heteroduplex that was able to block the formation of MBNL1-RNA complexes 
and disrupt complexes that had already formed. In vivo, intramuscular injection and 
electroporation of the (CAG) 25 antisense oligonucleotide morpholino in a transgenic mouse 
model that accumulate expanded CUG RNA and MBNL1 protein in nuclear foci in skeletal 
muscle, caused the reduction of nuclear foci and redistribution of MBNL1 protein. 14 weeks 
after treatment, myotonia was significantly reduced and ClC-1 function restored. The same 
approach was used to test the effect of this morpholino in an mbnl-1 deficient mouse, which 
mimics most of the splicing abnormalities of DM1. The morpholino had no effect, 
confirming that the morpholino specifically acts on the expanded repeats, which are not 
present in the mbnl1 knockout model (Wheeler et al., 2009).  
RNAi has also been used successfully to degrade mutant DMPK transcripts. SiRNA 
duplexes induce the specific cleavage of target RNAs in mammalian cells. Although most of 
the RNAi applications rely on the cytoplasmic effect of these molecules, it has been shown 
that RNAi phenomena can occur in the nucleus of primary DM1 cells by targeting nuclear 
retained DMPK mRNAs (Langlois et al., 2005). Krol et al. attempted to target particularly 
long hairpin structures formed from the interactions of CUG repeats rather than the 
targeting of nascent RNA in general. In this study it was demonstrated that these long CUG 
repeat hairpins are under the control of a ribonuclease Dicer, involved in the RNA 
interference pathway whose main function is to induce the fragmentation of double-
stranded RNA duplexes into shorter duplexes, which then act as endogenous siRNAs and 
trigger the downstream silencing effect. Furthermore, it was shown that the transduction of 
synthetic (CAG) 7 siRNAs into DM1 patient fibroblasts, leads towards a selective reduction 
of mutant transcripts containing long CUG repeats (Krol et al., 2007).  
An alternative approach to confront the toxicity of nuclear RNA retention is to block the 
binding of RNA-binding proteins to mutant DMPK transcripts using small chemical 
molecules with high affinity towards the mutant DMPK transcripts. The binding of these 
molecules on the mutant DMPK transcripts should prevent the binding and therefore the 
sequestration of RNA-binding proteins, such as MBNL1, and restore aberrant splicing 
(Mastroyiannopoulos et al., 2010). Several approaches have been performed with the most 
promising of these being the use of pentamidine, a small molecule that binds to the 
expanded CUG RNA sequence with high affinity and specificity causing reduction of CUG 
repeat foci formation and relieves MBNL1 sequestration (Warf et al., 2009). Moreover, 
pentamidine reversed the mis-splicing of 4 different pre-mRNAs affected in DM1 (Warf et 
al., 2009). Gareiss et al. used resin-bound dynamic combinatorial chemistry in order to 
identify the compounds that are able to inhibit MBNL1 binding to expanded CUG RNA. 
Screening of 11,325 members yielded several molecules with significant selectivity for 
binding to CUG repeat RNA. These compounds were also able to inhibit the interaction of 
expanded CUG with MBNL1 in vitro (Gareiss et al., 2008). In another report, the design of 
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high affinity ligands that bind to expanded CUG and CAG repeats and inhibit the formation 
of RNA-protein complexes that are implicated in DM1 was described (Pushechnikov et al., 
2009). Similarly, Garcia-Lopez et al. identified molecules that aim to target toxic CUG RNA 
transcripts when applied on a Drosophila model of DM1. By performing a positional 
scanning combinatorial peptide library screen, a D-amino acid hexapeptide (ABP1) that 
reduced CUG-induced toxicity in fly eyes and muscles was identified. Furthermore, ABP1 
reversed muscle histopathology and splicing misregulation of MBNL1 targets in DM1 
model mice. In vitro, ABP1 was found bound to CUG hairpins and induced a switch to a 
single-stranded conformation (Garcia-Lopez et al., 2011). In another study, Arambula et al. 
created a ligand with high nanomolar affinity to CUG RNA or CTG DNA repeats. This 
ligand is a triaminotriazine-acridine conjugate designed to hydrogen bond to both U’s or T’s 
in the U-U or T-T mismatch, interactions observed between binding of multi CUG and CTG 
repeats. This ligand was found to destabilize the interactions of MBNL1 with multi CUG 
repeats (Arambula et al., 2009).  
3.3 Induction of mutant DMPK transcripts nuclear export 
Few studies have attempted to determine whether the export of mutant DMPK transcripts is 
beneficial for the disease. The export of mutant DMPK RNA transcripts from the nucleus to 
the cytoplasm will have as a result the recovery of these cells from DM1 pathogenic events. 
The export of mRNA from the nucleus is a highly ordered and complicated procedure that 
implicates several molecules. As previously described, mutant DMPK RNA carrying long 
CUG repeats form haipin structures which then interact with proteins such as MBNL1 and 
CUGBP1. These interactions most possibly prohibit the export of these transcripts to the 
cytoplasm and cause nuclear retention in the form of foci.  
Mastroyiannopoulos et al. have demonstrated nuclear export of mutant DMPK 3’-UTR 
transcripts by introducing a viral post-transcriptional regulatory element. The WPRE 
(Woodchuck post-transcriptional regulatory element) has been widely used as an enhancer 
during transgene expression (Lee et al., 2005). It is also known to enhance gene expression 
through stimulation of nuclear RNA export (Donello et al., 1998). WPRE was inserted 
downstream of the 3’-end of a mutant DMPK 3’-UTR sequence and was shown to bypass 
nuclear entrapment. With the use of fluorescence in situ hybridization it was shown that the 
mutant DMPK transcripts that carried the WPRE sequence were localized mainly in the 
cytoplasm of C2C12 cells in the form of foci. WPRE mediated nuclear export enhanced 
muscle cell differentiation (Mastroyiannopoulos et al., 2005) and more specifically initial 
fusion of myoblasts (Mastroyiannopoulos et al., 2008). In another study, cardiac cells, 
identified from a transgenic mouse in which 400 CTG repeats were positioned downstream 
of the reporter LacZ gene and upstream of the bovine growth hormone polyadenylation 
signal, localized CUG aggregates exclusively in the cytoplasm of cells (Dansithong et al., 
2005). Aggregation of CUG RNAs within the cytoplasm resulted both in MBNL1 
sequestration and in approximately 2-fold increase in both nuclear and cytoplasmic 
CUGBP1 levels. Significantly, and despite these changes, RNA splice defects were not 
observed, and functional analysis revealed only subtle cardiac dysfunction. These results 
demonstrate that the presence of mutant DMPK transcripts in the cytoplasm in the form of 
foci is insufficient to elicit DM1 defects. Interestingly, Garcia-Lopez et al. described a 
transgenic Drosophila model expressing expanded CTG repeats which exhibit an extended 
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DM1 phenotype. Such as, muscle degeneration, ribonuclear formation, interactions with 
muscleblinds including misregulated alternative splicing of muscle genes and CUG 
depended central nervous system alterations. Genetic screens and functional assays on this 
Drosophila model identified the RNA export factor Aly as one of the causes of the phenotype. 
It has been shown that the Aly phenotype has a close relationship to mRNA export factors 
and EJC (exon junction complex) components. Mutations in Aly were shown to be 
associated with nuclear accumulation of CUG repeats. It is therefore important to study 
further the mRNA export pathway implicated in DM1 and identify candidate targets for 
repairing nuclear retention of the DMPK transcripts (Garcia-Lopez et al., 2008). Finally, a 
report proved in a very convincing way the benefit of exporting mutant DMPK transcripts 
to the cytoplasm. Wheeler et al. attempted to reverse the myotonic dystrophy symptoms in a 
well-studied animal model by interfering with the MBNL1 and CUG RNA hairpins 
interaction. The authors used a 25-nt antisense molecule, composed of CAG repeats, in order 
to prevent the interaction between MBNL1 and expanded CUG repeats by forming a 
heteroduplex with the hairpins. The oligonucleotide caused elimination of foci and released 
the trapped transcripts to the cytoplasm. Moreover, the antisense oligonucleotide repaired 
the defect of mis-splicing and restored the CLCN1 function and myotonia. This paper 
provided proof-of concept about the therapeutic potential of molecules that prevent the 
deleterious interactions between proteins and RNA in diseases. 
4. Discussion / conclusions 
In conclusion, almost 20 years after the discovery of DM1 mutation there is a very good 
understanding of the pathogenic mechanisms involved in DM1. As previously stated, the 
mutant DM1 RNA transcripts generate most of the pathological aspects of DM1. The 
retention of DMPK transcripts as ribonuclear inclusions in the nucleus of DM1 cells is 
considered to be an important pathogenic mechanism of the disease (Mankodi et al., 2000). 
A growing body of evidence showed that pleiotropic effects of aberrant interactions 
between mutant DMPK 3' UTR transcripts and RNA-binding proteins alter the metabolism 
of 'target' messenger RNAs (Ho et al., 2005; Jiang et al., 2004; Timchenko et al., 1996; 
Timchenko et al., 2001; Timchenko et al., 2004). Members of the muscleblind family (MBNL, 
MBXL and MBLL), which usually regulate mRNA splicing, have been shown to colocalize 
with the ribonuclear inclusions. The nuclear interactions of the MBNL proteins with the 
mutant DMPK 3' UTR transcripts, have shown to affect the splicing of various mRNAs, such 
as the insulin receptor (IR), troponin T (cTNT) and the muscle-specific chloride channel 
(ClC-1). Another RNA-binding protein, implicated in DM1 mechanism of pathogenesis, is 
CUGBP1. Extensive investigations have shown that CUGBP1 activity is increased in DM 
cells, and results in a trans-dominant effect on gene splicing.  
Although there is very good understanding of the consequences of the genetic mutation that 
causes DM1, the exact mechanisms responsible for the DM1 phenotype is not completely 
understood. DM1 pathogenesis is very complex and therefore, different potential 
approaches and multiple targets can be used for the development of DM1 therapies. To 
date, several attempts have been described as potential approaches for the therapy of the 
disease, either by restoring the levels of CUGBP1 and MBNL proteins, by targeting the 
mutant DMPK 3’ UTR transcripts or by the export of this toxic RNA from the nucleus to the 
cytoplasm of DM1 cells. All of the above approaches hold a great promise for the future 
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treatment of myotonic dystrophy, nevertheless it is also certain that more therapeutic 
approaches will be unveiled in the near future, which may be variations of the existing 
methods or novel ways to tackle the pathogenesis of the disease. Further research in DM1 
needs to be done in order to move these therapies forward into clinical trials for the cure of 
DM1 disease. 
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